Endo International PLC (ENDP) to Post Q3 2017 Earnings of $0.69 Per Share, William Blair Forecasts
Endo International PLC (NASDAQ:ENDP) – Investment analysts at William Blair upped their Q3 2017 EPS estimates for Endo International PLC in a research report issued to clients and investors on Wednesday. William Blair analyst T. Lugo now anticipates that the company will earn $0.69 per share for the quarter, up from their previous estimate of $0.68. William Blair has a “Market Perform” rating on the stock. William Blair also issued estimates for Endo International PLC’s Q4 2017 earnings at $0.64 EPS, FY2017 earnings at $3.48 EPS and FY2018 earnings at $3.17 EPS.
ENDP has been the subject of a number of other research reports. Oppenheimer Holdings, Inc. restated a “hold” rating on shares of Endo International PLC in a report on Sunday, July 23rd. Vetr upgraded Endo International PLC from a “strong sell” rating to a “sell” rating and set a $11.34 target price for the company in a report on Wednesday, May 17th. Zacks Investment Research cut Endo International PLC from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Canaccord Genuity set a $14.00 target price on Endo International PLC and gave the stock a “hold” rating in a report on Monday, May 22nd. Finally, Mizuho reiterated a “buy” rating and issued a $19.00 target price (up from $18.00) on shares of Endo International PLC in a report on Thursday, May 25th. Three investment analysts have rated the stock with a sell rating, sixteen have issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $15.54.
Endo International PLC (NASDAQ ENDP) opened at 7.94 on Thursday. The firm has a 50-day moving average price of $11.15 and a 200-day moving average price of $11.62. Endo International PLC has a 12-month low of $7.81 and a 12-month high of $24.93. The company’s market cap is $1.77 billion.
Endo International PLC (NASDAQ:ENDP) last announced its earnings results on Tuesday, August 8th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.19. The company had revenue of $875.73 million during the quarter, compared to the consensus estimate of $832.66 million. Endo International PLC had a positive return on equity of 37.58% and a negative net margin of 126.93%. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.86 earnings per share.
A number of hedge funds and other institutional investors have recently made changes to their positions in ENDP. Jensen Investment Management Inc. raised its position in shares of Endo International PLC by 24.2% in the second quarter. Jensen Investment Management Inc. now owns 30,620 shares of the company’s stock valued at $342,000 after buying an additional 5,960 shares in the last quarter. River & Mercantile Asset Management LLP acquired a new position in shares of Endo International PLC during the second quarter valued at about $1,851,000. Airain ltd acquired a new position in shares of Endo International PLC during the second quarter valued at about $387,000. Point View Wealth Management Inc. raised its position in shares of Endo International PLC by 16.6% in the second quarter. Point View Wealth Management Inc. now owns 13,331 shares of the company’s stock valued at $149,000 after buying an additional 1,900 shares in the last quarter. Finally, Blair William & Co. IL acquired a new position in shares of Endo International PLC during the second quarter valued at about $126,000. 93.00% of the stock is currently owned by institutional investors.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.